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118 A. Naguib et al.Results: RA patients’ ages ranged from 27 to 61 years (mean: 43.9 ± 11.6). They all had normal echo-
cardiographic ﬁndings. Serum visfatin levels were signiﬁcantly higher in the RA group (58.8 ± 6.6 ng/
ml) versus the controls (13.8 ± 8.11 ng/ml).ElevenRApatients (55%)had evidence of coronaryathero-
sclerotic changes with a mean CACS of 86.4 ± 360. There was a signiﬁcant correlation between serum
triglycerides andCACS (P= 0.014); however, therewas no signiﬁcant correlation of theCACSwith the
visfatin level, disease duration and DAS. Serum visfatin levels did not correlate with BMI or waist/hip
ratio. Compared to the RS group, the RA group was signiﬁcantly younger (43.9 ± 11.6 versus
56.8 ± 11.6 years, P< 0.0001). However, there was no statistically signiﬁcant difference in the fre-
quency of coronary artery calciﬁcation between the RA group (55%) and the RS group (32%)
(P= 0.65) and no signiﬁcant difference between the two groups in the CACS.
Conclusion: Coronary atherosclerosis occurs at least 10 years earlier in female patientswithRA. Serum
visfatin levels are elevated in RA patients; however, it does not explain early subclinical atherosclerosis.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Rheumatoid arthritis (RA) is characterized by a systemic
inﬂammatory state, involving several organs, including joints,
skin, eyes, lungs, and blood vessels.1 Coronary artery disease
(CAD) and heart failure represent the most common causes
of death in RA.2 Patients with RA have a higher morbidity
and mortality from myocardial infarction and allied disorders
as accelerated atherosclerosis than the general population.3
The risk of CAD in RA patients which precedes the ACR
criteria-based diagnosis of RA cannot be explained by an
increased incidence of traditional CAD risk factors in RA
patients.2
Immune cells and soluble inﬂammatory mediators play a
crucial role in RA pathogenesis.4 These inﬂammatory pro-
cesses resemble those in other chronic inﬂammatory diseases,
such as atherosclerosis.5 Expression of proinﬂammatory cyto-
kines and inﬂammatory mediators inﬂuences all stages of ath-
erosclerosis development, from early atheroma formation to
thrombus development responsible for events as myocardial
infarction.6 The chronic systemic inﬂammation in RA can be
considered as an independent risk factor for the development
of atherosclerosis.7–9
Visfatin is one of the adipokines produced and secreted pri-
marily by visceral white adipose tissue.10 Overexpression of
visfatin in disease is thought to be more than simply a bio-
marker of inﬂammation.11 It has pro-inﬂammatory as well as
immunomodulating properties through its extracellular
form.12 In rheumatoid arthritis, visfatin level was found to
be elevated in plasma and synovial ﬂuid of patients compared
to control subjects.13–15 In one study, serum and synovial ﬂuid
visfatin was found to be correlated with the degree of inﬂam-
mation and clinical disease activity.15
On the other hand, visfatin was recently shown to play a
role in plaque destabilization.16 Its role in atherosclerosis
was studied and its plasma levels were signiﬁcantly higher in
chronic CAD and acute coronary syndromes compared with
control patients17 and correlated with the presence of CAD
independent of other cardiovascular risk factors.18
Unlike atherosclerotic non-RA patients, the role of visfatin
in accelerating atherosclerosis in RA patients was not clearly
deﬁned and needs further elucidation owing to the scarceness
of available research. It was found by some authors to be ele-
vated in RA patients without being correlated with carotid
intima-media thickness; a predictor of atherosclerosis19 andby others to be not independently associated with the coronary
artery calcium score (which detects CAD).20 Identiﬁcation of
the role of visfatin in atherosclerosis in RA patients should
add to better recognition and management of cardiovascular
risk in RA and hence it may be a future therapeutic target.
1.1. Aim
To investigate the effect of visfatin on the cardiovascular sys-
tem in patients with rheumatoid arthritis.2. Methods
The study included 20 female patients diagnosed with RA,
according to the 1988 revised ACR criteria,21 who attended
the Physical Medicine, Rheumatology and Rehabilitation
department at the Faculty of Medicine, Alexandria University.
Exclusion criteria included any systemic illness as endocrine
disorders, other associated rheumatic diseases, history of myo-
cardial infarction, any malignancy, chronic kidney or liver
disease.
Detailed history taking about their condition including dis-
ease duration, morning stiffness and drug history was carried
out. All patients underwent thorough clinical examination
with special attention to cardiac and articular examination.
Body mass index (BMI) (weight in kilograms/height in square
meters) was determined. Waist and hip circumference measure-
ment was performed to calculate the waist/hip ratio.22 Disease
activity assessment by the disease activity score (DAS 28) was
carried out.23 The formula employed in this study was the
DAS28 with four variables:
DAS28 ¼ 0:56 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðTEN28Þp þ 0:28 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðSW28Þp þ 0:70 lnðESRÞ
þ 0:014 ðGHÞ. (TEN 28: 28 joint count for tenderness, SW 28:
28 joint count for swelling, Ln ESR: the natural logarithm of
Westergren’s erythrocyte sedimentation rate, GH: general
health or patient’s global assessment of disease activity on
the visual analog scale (VAS) of 100 mm).
Laboratory investigations were performed, which included
complete blood count and ESR. Serum visfatin levels were
measured (visfatin was assayed using a commercially available
ELISA kit, Phoenix Pharmaceuticals, Belmont, CA) (interas-
say coefﬁcient of variation 4.9%) drawn after an overnight fast
and stored at 70 C). Lipid proﬁle assessment, which
included total cholesterol (TC), high and low density lipopro-
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(TG) was performed.
2.1. Cardiac assessment included
 Echocardiography: using HP envisor 1500 for the evalua-
tion of left ventricular dimension and function and to
exclude valvular lesions and pericardial involvement.
 Detection of early atherosclerosis: by identifying the coro-
nary artery calcium score (CACS): multislice computed
tomography (MSCT) data acquisition: examinations were
performed using Toshiba 64-slice multislice aquilion
systems (Toshiba Medical Systems, Tokyo, Japan).24 A
prospectively triggered coronary calcium scan was acquired
with the following parameters: collimation 4 · 3.0 mm,
gantry rotation time 400 ms, tube voltage and tube current
120 kV and 200 mA, respectively, and the temporal window
was set at 75% after the R-wave. CACS was assessed with
the application of dedicated software (Vitrea 2). Coronary
artery calcium was identiﬁed as a dense exceeding the
threshold of 130 HU. An overall Agatston score was
recorded for each patient.
A control group of 15 healthy females matching in age,
BMI and waist/hip ratio had their serum visfatin level mea-
sured. In addition to a risk stratiﬁcation (RS) group of 30 fe-
male patients referred for calcium scoring. The study was
explained to the participants and an informed consent was gi-
ven by each one. The study was approved by the local ethics
committee.
2.2. Statistics
Data was statistically analyzed using SPSS (Statistical Package
for the Social Sciences) version 11 for windows. Descriptive
data were presented as range, mean ± SD and frequencies.
Mann–Whitney test was used to compare between groups.
Spearman correlation coefﬁcient was used to test the relation-
ship between various variables. P-value 60.05 was considered
signiﬁcant. The cut off value of the serum visfatin level = -
mean ± 1 SD. Moreover, patients were considered to have
an abnormal lipid proﬁle if the serum level exceeded the upper
limit of normality.
3. Results
The mean age of the patients was 43.9 ± 11.6 years (range: 27–
60 years). The mean disease duration was 3.5 ± 3.4 years
(range: 3–14 years) and the mean DAS28 was 5.4 ± 0.46
(range: 4.5–6.4). None of the examined patients had extra-
articular involvement. Regarding the lipid proﬁle of the stud-
ied RA patients, it was found that the mean serum level of
the TC, HDL, LDL, and TG were 220.65 ± 43.9,
48.45 ± 8.5, 145 ± 38.23, and 109.3 ± 29.1 mg/dl, respec-
tively. Furthermore, individual data analysis revealed that 12
patients (60%) had elevated serum TC level (>200 mg/dl).
Two patients (10%) had low serum HDL levels (<40 mg/dl)
i.e. high risk for the development of atherosclerosis, while 18
patients (90%) had moderate risk (40–65 mg/dl). Moreover,
19 patients (95%) had elevated serum LDL (>100 mg/dl).
None of the studied patients had elevated serum TG. Themean ESR (ﬁrst hour) was 31.6 ± 13.5 mm (range: 18–55).
All patients were treated with appropriate doses of methotex-
ate with concomitant non-steroidal anti-inﬂammatory drugs
(NSAIDs).
Table 1 demonstrates the comparison between RA patients
and the healthy control group regarding their age, anthropo-
metric measurements and serum visfatin level. There was a sta-
tistically signiﬁcant increase in the mean serum visfatin level of
RA patients compared to the control group (Z= 5.096,
P= 0.000).
All RA patients had elevated serum visfatin levels (exceed-
ing the high cut off value i.e. 21.43 ng/ml). However, no statis-
tically signiﬁcant correlations were found for the serum
visfatin level with the clinical measurements and lipid proﬁle
of the RA patients (Table 2).
In the current study, although all RA patients had no clin-
ical evidence of cardiac involvement or echocardiographic
changes, their mean CACS was 86.4 ± 360.3 Agatston score.
Among the studied patients, 11 (55%) had evidence of coro-
nary atherosclerotic changes with a mean CACS of
157.1 ± 484.2 Agatston score. However, comparison between
RA patients with coronary artery calciﬁcation (CAC) and
those with no CAC revealed no signiﬁcant differences regard-
ing clinical ﬁndings, anthropometric measurements and labo-
ratory ﬁndings apart from a signiﬁcant increase in serum TG
in patients with CAC (Z= 2.091, P= 0.037) (Table 3).
CACS had a signiﬁcant positive correlation with serum tri-
glycerides (P = 0.014), whereas, it had no signiﬁcant correla-
tions with other clinical and laboratory parameters as disease
duration, disease activity, and serum visfatin levels (P< 0.05).
Compared to the risk stratiﬁcation group (RS), the RA pa-
tients were signiﬁcantly younger; their mean age was
43.85 ± 11.56, while that of RS group was 56.8 ± 11.6 years
(P= 0.0001). However, there was no signiﬁcant difference be-
tween both groups regarding the frequency of coronary artery
calciﬁcation (55% in RA versus 32% in RS groups; P= 0.65).
Moreover, there was no signiﬁcant difference between both
groups regarding the mean CACS (157.1 ± 484.2 for RA ver-
sus 111.2 ± 286.5 Agatston score for RS).
4. Discussion
Atherogenesis is accelerated in RA patients5 and increases mor-
tality from acute cardiovascular events.25–27 Several immune
cells and solublemediators play a crucial role in the pathogenesis
of atherosclerosis in RA.4 Among these mediators is visfatin
which is an adipokine produced and secreted primarily by vis-
ceral white adipose tissue (WAT)10 and represents an additional
link between adipose tissue and inﬂammation.28
In the current study, serum visfatin levels were signiﬁcantly
elevated in RA patients compared to controls (58.82 ± 6.58
versus 13.54 ± 7.9) and the serum level exceeded the high
cut off value in all patients. This is in agreement with Otero
et al.13 Brentano et al.15 and Rho et al.29 However, in the pres-
ent study, serum visfatin levels did not correlate with DAS 28
or with ESR. This signiﬁes that in spite of being elevated, ser-
um visfatin may not directly reﬂect the pathological changes
(the inﬂammatory process) of RA in this study. In fact, the role
of visfatin in the context of RA is unclear; it might involve the
modulation of the inﬂammatory or immune response or the
increased level could simply be an epiphenomenon.30
Nevertheless, assessment of synovial ﬂuid visfatin, or its
Table 1 Comparison between RA patients and the healthy control group regarding their age, anthropometric measurements and
serum visfatin level (Mann–Whitney test).
Parameters RA patients mean ± SD Controls mean ± SD Z P
Age (years) 43.85 ± 11.56 38.75 ± 9.53 1.307 0.191
Serum visfatin level (ng/ml) 58.82 ± 6.58 13.54 ± 7.9 5.096* 0.000
Weight (kg) 78.1 ± 14.9 73.1 ± 16.04 1.402 0.161
Height (meter) 157.1 ± 4.37 160.94 ± 7.1 1.882 0.06
BMI (kg/m2) 31.28 ± 6.6 28.17 ± 5.55 1.64 0.101
Waist circumference (cm) 94.43 ± 12.3 93 ± 12 0.383 0.702
Hip circumference (cm) 111.73 ± 14.9 105.06 ± 13.3 1.817 0.69
Waist/hip ratio 0.85 ± 0.07 0.89 ± 0.13 0.877 0.38
Kg, kilogram; ng/ml, nanogram/milliliter; BMI, body mass index; cm, centimeter.
* Signiﬁcant if P< 0.05.
Table 2 Correlation between the serum visfatin level and the
clinical data, anthropometric measurements and laboratory
data of the RA patients (Spearman’s correlation coefﬁcient
test).
Parameters r P
Age (years) 0.153 0.521
Disease duration 0.011 0.962
DAS28 0.150 0.529
BMI (kg/m2) 0.185 0.435
Waist/hip ratio 0.104 0.662
Serum cholesterol 0.119 0.617
Serum triglycerides 0.092 0.700
Serum HDL 0.068 0.776
Serum LDL 0.140 0.556
ESR (1st hour) 0.2 0.397
BMI, body mass index; HDL; high density lipoproteins; LDL, low
density lipoproteins.
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the pathological events taking place inside the joint and may
reﬂect disease activity. Moreover, serum visfatin levels did
not correlate with the anthropometric measurements of the
studied RA patients including waist/hip ratio and waist cir-
cumference which is a simple indicator of abdominal visceral
adipose mass.22,31 Although visfatin is secreted by visceral
WAT10, the lack of correlation between both points out to
other possible sources and or causes which modulate serum
visfatin levels in RA. As visfatin synthesis is regulated by sev-
eral factors including IL-6 and TNFa,30 it is possible that visf-
atin levels increase in RA as a direct consequence of increased
IL-6 and TNFa.30,32 Moreover, it may be secreted by activated
peripheral lymphocytes33 monocytes, macrophages and den-
dritic cells in response to inﬂammatory stimuli.16,34,35 Alto-
gether, this may increase the level of serum visfatin
independent of visceral WAT in RA.
Another speculation is that the high level of serum visfatin
in RA patients may be due to a sort of alteration in the gene
encoding visfatin as a result of the RA triggering factors: a
condition which may lead to an increase in its production
autonomously independent of disease activity or visceral obes-
ity. Our results also revealed that serum visfatin levels did not
correlate with patients’ ages or disease duration denoting that
its level is not a cumulative phenomenon related to time lapse,rather it may be inﬂuenced by short-term ﬂuctuating factors
like inﬂammatory mediators. Gonzalez-Gay et al.36 also did
not ﬁnd any correlation between serum visfatin levels and pa-
tients’ ages, disease duration, BMI, ESR, CRP, lipids, and
DAS 28 in non-diabetic RA patients.
In the current study, none of the RA patients had clinical or
echocardiographic evidence of cardiovascular involvement, yet
55% had CAC denoting subclinical atherosclerosis, detected
by MSCT, a technique that provides a reproducible and quan-
titative method for the detection of subclinical coronary artery
sclerosis and yields information about additional future car-
diovascular risk.37,38 CAC provides a better estimate of the
disease than luminal stenosis39 because less obstructive plaques
give rise to more occlusion than the more obstructive plaques
due to their greater number.40 Although CAC directly detects
hard or calciﬁed plaques only, it serves as a marker for soft and
non-calciﬁed plaques as in the majority of patients both types
of plaques coexist proportionately.41 Therefore, a CACS of
zero is a technically acceptable result that makes the presence
of atherosclerotic plaques including unstable ones very unli-
kely.42 Thus, in the present study, the 45% of RA patients
who had a CACS of zero were unlikely to have subclinical ath-
erosclerosis. On the other hand, the 55% of RA patients who
had CAC (though asymptomatic) had the risk to develop CAD
as in some studies CACS provided an incremental progressive
value when added to the conventional risk factors of CAD.43,44
The development of preclinical atherosclerosis is more pre-
valent and accelerated in RA patients and occurs indepen-
dently of the traditional risk factors.45 In the current study,
two important factors related to atherosclerosis were investi-
gated, namely visfatin and the lipid proﬁle.
Dyslipidaemia (as a traditional atherosclerotic risk factor)
plays a crucial role in the development of atherosclerosis, a pro-
cess which is accelerated by the endothelial dysfunction charac-
terizing RA. The increased spaces between altered endothelial
cells in RA patients permit the entry of LDL, which is retained
in the intima, oxidized with subsequent recruitment of circulat-
ing leukocytes within atherosclerotic plaques.46,47 On the other
hand, decreased levels of HDL may accelerate atherosclerosis
because they exert atheroprotective functions.48,49
In this study, almost all RA patients had increased serum
TC and increased serum LDL together with a general tendency
to low levels of HDL. Thus, the dyslipidaemia of the studied
RA patients was matching to a great extent with the
atherogenic lipid proﬁle which is typically characterized by
Table 3 Comparison between RA patients with coronary artery calciﬁcation (CAC) and those with no CAC regarding the clinical,
anthropometric and laboratory data (Mann–Whitney test).
Parameters RA patients with no CAC
N= 9 (45%)
RA patients with CAC
N= 11(55%)
Z P
Age (years) 39.7 ± 10.3 47.27 ± 11.8 1.446 0.148
Disease duration (years) 2.5 ± 2.37 4.3 ± 4.9 0.384 0.701
DAS28 5.5 ± 0.52 5.4 ± 0.42 0.117 0.907
Pulse (beats/minutes) 65.78 ± 2.3 66.1 ± 1.92 0.236 0.813
Ejection fraction (%) 69 ± 3.6 69 ± 4.7 0.00 1
CACS 0 157.1 ± 484.2 3.946 0.000
BMI 30.1 ± 6.2 32.3 ± 7 0.57 0.569
Waist/hip ratio 0.84 ± 0.07 0.86 ± 0.07 0.381 0.703
Serum visfatin level (ng/ml) 58.3 ± 6 59.3 ± 7.3 0.418 0.138
Serum cholesterol (mg/dl) 212.2 ± 38.67 227.6 ± 48.4 0.722 0.470
Serum triglycerides (mg/dl) 98.9 ± 31.6 117.82 ± 25.2 2.091* 0.037
Serum HDL (mg/dl) 49.4 ± 7.9 47.6 ± 9.2 0.228 0.819
Serum LDL (mg/dl) 132.5 ± 26.8 155.3 ± 44.1 1.178 0.239
ESR(1st hour) 32.11 ± 15.6 31.1 ± 12.23 0.233 0.816
BMI, body mass index; HDL, high density lipoproteins; LDL, low density lipoproteins; ng/ml, nanogram/milliliter; mg/dl, milligram/deciliter.
* Signiﬁcant if P< 0.05.
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in serum HDL levels.50 Speciﬁcally, an increase in the TC/
HDL ratio, which represents an atherogenic index, is an
important prognostic marker for cardiovascular disease.51
The risk of myocardial infarct (MI) increases considerably
when this ratio is higher than 5, and it should ideally be 4 or
less.51 In this study, 25% of the RA patients had an athero-
genic index >5 (data not shown), denoting a higher risk of
atherosclerosis.51
Despite having an atherogenic lipid proﬁle in almost all RA
patients, only 55% had CAC. Thus, the role of dyslipidaemia
as a mechanism of CAD is doubtful in those patients because
the rest of our patients had no CAC in spite of having a pro-
atherogenic lipid proﬁle. Furthermore, comparison between
patients with and without CAC revealed no signiﬁcant differ-
ence regarding TC, HDL, and LDL. However, there was a ten-
dency for the lipid proﬁle of the patients with no CAC to be
less pro-atherogenic though not signiﬁcant. Thus, it can be
concluded that the role of dyslipidaemia in the pathogenesis
of subclinical atherosclerosis in RA patients should be viewed
in the context of other operating mechanisms.4 Moreover, it is
possible that other fractions of speciﬁc lipoprotein particles
such as very low density lipoproteins (VLDL) or sub-fractions
of HDL52,53 may play a signiﬁcant role in atherogenesis in RA.
On the other hand, although all the studied RA patients
showed normal serum TG levels, patients with CAC showed
a signiﬁcant increase in its mean value (117.82 ± 25.2) com-
pared to those without CAC (98.9 ± 31.6). Moreover, there
was a signiﬁcant positive correlation between CACS and the
serum TG levels in RA patients denoting that serum TG is
probably relevant to atherogenesis. In non-RA patients, hyper-
triglyceridemia is considered to be a risk factor for CAD. The
possible causes include increased production of atherogenic
chylomicrons, VLDL remnants and more dense atherogenic
LDL particles, in addition to the interaction between serum
TG and the ﬁbrinolytic/coagulation system.54
An association between moderately high TG levels within
the normal range and the development of CAD was demon-
strated suggesting a cumulative effect of exposure to high
TG levels.55 Nevertheless, it is to be noted that TG levels aresubjected to variations by many factors including life style
modiﬁcations, BMI changes and aerobic exercise.56–58 There-
fore, a single measurement of TG levels may not be a reliable
indicator for the long term effects of hypertriglyceridemia.
While our study demonstrated a signiﬁcant positive correlation
between serum TG and CAD in RA, others did not.59,60
In the current study, almost all patients received methotrex-
ate and NSAIDs which may inﬂuence serum lipid levels as re-
ported by some studies.61,62 Accordingly, the detection of
serum lipids in early RA or before the commencement of ther-
apy may be more representative of the lipid proﬁle in RA as
shown in a study performed by Georgiadis et al.50 For the
same reason i.e. the effect of treatment, rheumatoid factor
seropositivity was not considered in our study.63,64
The second factor studied in the current work in the context
of atherosclerosis was serum visfatin. Through cytokine-like
activity, visfatin is suggested to play a role in unstable athero-
sclerosis. Dahl et al.16 found increased visfatin expression from
the carotid artery of patients with stroke and at the sites of pla-
que rupture in patients with acute MI. They also found upreg-
ulation of visfatin in macrophages from human unstable
atherosclerotic lesions and suggested that visfatin plays an
important role in atherogenesis and plaque destabilization.
In RA, the permanent over-expression of cellular adhesion
molecules and proinﬂammatory cytokines may participate in
accelerated atherogenesis.19 In this context, visfatin was found
to enhance the expression of ICAM-1 and VCAM-1 and oth-
ers65 whose expression on the endothelial cell surface is the ini-
tial step in atherogenesis.65,66 Thus, it can be assumed that
visfatin may play a role in the acceleration of atherogenesis
in RA. However, in the current study, CACS did not correlate
with serum visfatin levels in RA patients. There was also no
signiﬁcant difference between the mean serum visfatin level
in RA patients with and without CAC (59.3 ± 7.3 versus
58.3 ± 6). This signiﬁes that visfatin did not play a direct role
in atherosclerosis in RA patients. This is in agreement with
Rho et al.20 who studied the effect of adipokines on atheroscle-
rosis in RA patients using electron beam CT to detect CAC.
They found that serum visfatin was not associated with
CAC. Moreover, Ozgen et al.19 studied the association
122 A. Naguib et al.between serum visfatin levels and common carotid intima-
media thickness in some rheumatic diseases including RA.
They found increased serum visfatin levels in RA patients com-
pared to other rheumatic diseases, yet its level was not corre-
lated with intima-media thickness. Thus, based on this, it
seems that the role of visfatin in atherogenesis is different in
RA patients. This can be attributed to the highly complicated
multifactorial pathogenesis of atherosclerosis in RA. These
factors include various leukocytic populations orchestrated
by several cytokines (among which TNFa is of particular
importance), chemokines, growth factors, and hormones.46
Therefore, the contribution of each factor to atherogenesis in
RA may differ among individuals. Hence, the role of visfatin
as a single factor is not stereotyped in all patients.
On the other hand, 45% of our patients were not athero-
sclerotic in spite of having increased serum visfatin levels sug-
gesting that it is unlikely to play a direct role in CAD and
another mechanism may be involved such as a relative increase
in serum TG.55 It is worth mentioning that visfatin may exert a
variety of insulin-mimetic effects, including enhancing glucose
uptake and increasing TG synthesis,67 an issue which may rep-
resent an indirect link between visfatin and atherosclerosis in
some patients.
In the present study, CACS did not correlate with patients’
anthropometric measurements supporting the multifactorial
nature of atherogenesis in RA (not dependant mainly on
BMI or visceral fat). CACS also was not correlated with pa-
tients’ ages or disease duration. This is unlike the study per-
formed by Del Rinco´n et al.8 who concluded that patients
with prolonged RA have more atherosclerosis than age-
matched patients with more recent disease onset. They sug-
gested that systemic inﬂammation may amplify the age-related
risk of cardiovascular diseases. Moreover, CACS did not cor-
relate with DAS28. This may be related to the inherent nature
of DAS which considers mainly the articular involvement as an
indicator of RA disease activity, while CAD is an extraarticu-
lar manifestation. Accordingly, it is conceivable that DAS can-
not reﬂect the degree of CAC.
Comparison between the RA patients and the RS group re-
cruited for determination of CACS revealed that RA patients
were signiﬁcantly younger and had comparable CACS. This
supports the notion that RA is a risk factor that causes prema-
ture atherosclerosis45 (independent of other risk factors). This
should encourage aggressive therapy to induce remission and
hence arrest or prevent the development of CAD.45
From this study it can be concluded that serum visfatin lev-
els are signiﬁcantly elevated in RA patients. However, this
could not be explained in terms of increased disease activity,
visceral obesity or inﬂammatory markers. It could not also
be considered as a factor responsible for CAC in the studied
RA patients. Thus, the source of its production, factors inﬂu-
encing its serum level and its pathogenetic role in RA espe-
cially in CAD remain to be clariﬁed. A longitudinal study on
a larger number of RA patients is needed to further study
the role of visfatin in CAD taking into consideration the role
of the other confounding risk factors.
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